SynthesisFrontiers in psychiatry2023
Accuracy of Raman spectroscopy in the diagnosis of Alzheimer's disease.
Synthesis in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 9 citations in OpenAlex.
- Raman Spectroscopy for Probing Pathological Protein Aggregates: Potential and Perspectives for Advanced Diagnostic Applications.International journal of molecular sciences · 2026Review
- 3D Hyperspectral Data Analysis with Spatially Aware Deep Learning for Diagnostic Applications.Analytical chemistry · 2025Article
- Unlocking Preclinical Alzheimer's: A Multi-Year Label-Free In Vitro Raman Spectroscopy Study Empowered by Chemometrics.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the accuracy of Raman spectroscopy in the diagnosis of Alzheimer's disease. Methods: Databases including Web of Science, PubMed, The Cochrane Library, EMbase, CBM, CNKI, Wan Fang Data, and VIP were electronically searched for studies on Raman spectroscopy in diagnosis of Alzheimer's disease from inception to November 2022. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias in the included studies. Then, meta-analysis was performed using Meta-Disc1.4 and Stata 16.0 software. Results: A total of eight studies were finally included. The pooled sensitivity of Raman spectroscopy was 0.86 [95% CI (0.80-0.91)], specificity was 0.87 [95% CI (0.79-0.92)], positive likelihood ratio was 5.50 [95% CI (3.55-8.51)], negative likelihood ratio was 0.17 [95% CI (0.09-0.34)], diagnosis odds ratio and area under the curve of SROC were 42.44 [95% CI (19.80-90.97)] and 0.931, respectively. Sensitivity analysis was carried out after each study was excluded one by one, and the results showed that pooled sensitivity and specificity had no significant change, indicating that the stability of the meta-analysis results was great. Conclusions: Our findings indicated that Raman spectroscopy had high accuracy in the diagnosis of AD, though it still did not rule out the possibility of misdiagnosis and missed diagnosis. Limited by the quantity and quality of the included studies, the above conclusions need to be verified by more high-quality studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.